scholarly journals Correction to: A Case of Two Adult Brothers with Wiskott‑Aldrich Syndrome, One Treated with Gene Therapy and One with HLA‑Identical Hematopoietic Stem Cell Transplantation

Author(s):  
Giulia Consiglieri ◽  
Francesca Ferrua ◽  
Alessandro Aiuti ◽  
Maria Pia Cicalese ◽  
Blood ◽  
2008 ◽  
Vol 111 (1) ◽  
pp. 439-445 ◽  
Author(s):  
Hulya Ozsahin ◽  
Marina Cavazzana-Calvo ◽  
Luigi D. Notarangelo ◽  
Ansgar Schulz ◽  
Adrian J. Thrasher ◽  
...  

Wiskott-Aldrich syndrome (WAS) is a rare X-linked immunodeficiency with microthrombocytopenia, eczema, recurrent infections, autoimmune disorders, and malignancies that are life-threatening in the majority of patients. In this long-term, retrospective, multicenter study, we analyzed events that occurred in 96 WAS patients who received transplants between 1979 and 2001 who survived at least 2 years following hematopoietic stem-cell transplantation (HSCT). Events included chronic graft-versus-host disease (cGVHD), autoimmunity, infections, and sequelae of before or after HSCT complications. Three patients (3%) died 2.1 to 21 years following HSCT. Overall 7-year event-free survival rate was 75%. It was lower in recipients of mismatched related donors, also in relation with an older age at HSCT and disease severity. The most striking finding was the observation of cGVHD-independent autoimmunity in 20% of patients strongly associated with a mixed/split chimerism status (P < .001), suggesting that residual-host lymphocytes can mediate autoimmune disease despite the coexistence of donor lymphocytes. Infectious complications (6%) related to splenectomy were also significant and may warrant a more restrictive approach to performing splenectomy in WAS patients. Overall, this study provides the basis for a prospective, standardized, and more in-depth detailed analysis of chimerism and events in long-term follow-up of WAS patients who receive transplants to design better-adapted therapeutic strategies.


2010 ◽  
Vol 21 (3) ◽  
pp. 241-250 ◽  
Author(s):  
Maria Teresa Lupo-Stanghellini ◽  
Elena Provasi ◽  
Attilio Bondanza ◽  
Fabio Ciceri ◽  
Claudio Bordignon ◽  
...  

2014 ◽  
Vol 20 (2) ◽  
pp. S231
Author(s):  
Sakara Hutspardol ◽  
Adam Gassas ◽  
John Doyle ◽  
Muhammad Ali ◽  
R. Maarten Egeler ◽  
...  

Blood ◽  
2002 ◽  
Vol 99 (12) ◽  
pp. 4626-4628 ◽  
Author(s):  
Ted S. Strom ◽  
Xiuling Li ◽  
John M. Cunningham ◽  
Arthur W. Nienhuis

Allogeneic hematopoietic stem cell transplantation (HSCT) corrects the Wiskott-Aldrich syndrome (WAS) phenotype. However, the toxicity and mortality frequently associated with this approach warrant the exploration of new therapeutic strategies. Transplantation studies of a murine model of WAS deficiency have been limited by the occurrence of a radiation-induced fatal exacerbation of a pre-existing colitis in the peritransplantation period. Here we demonstrate that when crossed to a C57/B6 background, WAS-deficient males show little if any colitis and reliably survive HSCT. We show that HSCT corrects the hematologic and functional deficiencies of WAS knockout mice. These results strengthen the analogy between murine and human WAS and provide a basis for the use of WAS-deficient mice to explore novel approaches for correction of the disease phenotype.


Sign in / Sign up

Export Citation Format

Share Document